Close Menu

Biocartis

Biocartis' platform, acquired from Philips earlier in the year, is meant to address a market that doesn't need large numbers of test batches being run on a regular basis.

BioMérieux also has made a €9 million ($12.8 million) equity investment in Biocartis as part of the deal.

Movers & Shakers: Apr 9, 2010

Premium

Pietro Scalfaro

Debiopharm, which participated in the financing round as a new investor, announced separately that it will be collaborating with Biocartis to develop companion diagnostics for therapies in the areas of oncology and infectious disease.

The Swiss firm said that it will use the cash to accelerate development and validation of the first version of its forthcoming molecular diagnostics platform, which will incorporate nucleic acid sample prep technology recently acquired from Royal Philips Electronics.

The platform features new nucleic acid sample prep and amplification technologies and will be developed for a wide range of DNA and RNA molecular diagnostic testing, including in oncology and infectious diseases, according to a Biocartis executive.

Biocartis has formed a Dutch subsidiary that will collaborate with Philips on further developing the molecular diagnostics platform.

Biocartis is developing a multiplex, molecular diagnostics system.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.